The present invention relates to a method for determining the distinctive nutritional requirements of a patient with specific nutritional needs and providing a composition meeting the distinctive nutritional requirements of said patient.

Choline alfoscerate is a drug used to improve cerebrovascular diseases and brain metabolism. It is a drug with proven safety, which has no effect on the kidney and liver and with no severe side effect reported. When administered to a patient with muscle cramps, it can significantly reduce pain and the occurrence of muscle cramps. Accordingly, it may be used as an active ingredient in a pharmaceutical composition for treating or preventing muscle cramps and a health functional food composition for improving muscle cramps and may also be used for a method for treating muscle cramps by administering choline alfoscerate. In addition, choline alfoscerate may also be used to prepare a medication for treating muscle cramps.

The present invention relates to a novel Toxoplasma gondii GRA8-derived recombinant peptide, and a pharmaceutical composition and functional food for preventing or treating cancer, which includes the same as an active ingredient. The Toxoplasma gondii GRA8-derived recombinant peptide according to the present invention is a novel recombinant peptide in which a specific mitochondrial targeting sequence and an ATP5A1/SIRT3 sequence of GRA8 are conjugated to an acidity-triggered rational membrane (ATRAM), and has considerably improved efficacy in which an inhibitory concentration 50 (IC50) is improved up to 200-fold (in vitro) or 500-fold (in vivo), compared with a conventional GRA8-derived peptide (rGRA8). In addition, since the peptide treatment shows a notably distinct therapeutic effect in mouse models with cancer, the peptide may be effectively used in a pharmaceutical composition or functional food for preventing or treating cancer.

Nutraceuticals Composition A (metabolic capacity enhancing compositions) comprises extraction or powder from White Kidney Bean, Green Tea, Green Coffee Bean, Garcinia Cambogia, Gymnema Sylvestre, L-Carnitine, Guarana, Ginger Root, Dandelion Root, Capsicum Cayenne, Licorice Root, Ascorbic Acid, d-Calcium Pantothenate, Pyridoxine HCl, Potassium Chloride, Magnesium Carbonate, and Chromium Yeast. Nutraceuticals Composition B (immunity capacity enhancing compositions) comprises extraction or powder from Grape Seed, Ginseng, Garlic, Rosehips, Green tea (Decaf), Astragalus, Beta Glucan Yeast, Reishi, Shitake, Maitake, Agricus blazei, Turkey Tail, Cordyceps, and Coenzyme CoQ10. The methods to make a synergistic Composition A and Composition B are formulated and are capable to provide a bioavailable dietary supplement and phytonutrients that can help modulate metabolism and enhance the human immune system. The supplementation, consumption, of these nutraceutical formulas have preventive and therapeutic roles for chronic diseases, and thus provide anti-aging effects.

A method for monitoring and incentivizing food purchasing includes presenting a prompt for regarding a first food product code, receiving an input regarding the first food product and rating the healthiness of the first food product. The computerized method does the same for a second food product. A healthiness rating is determined for each of the first food item, the second food item and the combination of the food items. The healthiness rating includes a biometric input for setting a calorie budget and a health profile for determining the best mix of food nutrient values for a particular health profile. Incentives are provided based on the healthiness rating of the combination. A computer system can be employed to implement the above method. An instruction set stored in memory implements the method and causes the computer hardware and software to implement the method.

The disclosed compositions, systems and methods relate to a dietary supplement for human consumption and comprises a combination of paraxanthine and tyrosine and/or taurine and optionally other compounds that modulate the effects of a combination of paraxanthine and tyrosine and/taurine. Further disclosed are methods of use of the foregoing compositions for improvement of at least one of endurance performance, mood, vigor, lipolysis, energy expenditure, exercise performance, and/or decreased appetite.

The invention relates to compositions and methods for adjusting digestive or absorptive rates and ratio of foods or drinks or reducing a digestive solution. Particularly, the invention provides a composition comprising an insoluble dietary fiber and a prebiotic gel and its application in reducing digestive or absorptive rates and ratio of foods or drinks.

The present invention includes compositions and methods for reducing at least one of fasting blood glucose, total cholesterol, LDL cholesterol, VLDL cholesterol, a cholesterol:HDL ratio, triglycerides, or increasing a healthy microbiome comprising a synergistic amount of a fiber blend, a polyphenol blend, and a multivitamin supplement in an amount sufficient to lower at fasting blood glucose, total cholesterol, LDL cholesterol, VLDL cholesterol, a cholesterol:HDL ratio, triglycerides, or increasing a healthy microbiome.

Provided is a composition for preventing or treating obesity including a mixed extract of Cinnamomi twigs, and more particularly, a pharmaceutical composition for preventing or treating obesity including a mixed extract of Cinnamomi twigs and Moutan root bark, a health functional food composition of feed composition for preventing or alleviating obesity including the composition, and a method of preventing or treating obesity including administering the pharmaceutical composition to an individual having obesity or a risk of developing obesity. The mixed extract of Cinnamomi twigs and Moutan root bark may inhibit fat absorption in the intestinal tract and increases in body weight causing obesity by single-dose administration, reduce lipid content in the blood, decrease weight and size of adipocytes, effectively inhibit accumulation of fat in liver tissue, and inhibit diarrhea, a serious side effect of Xenical™, by long-term administration.

Methods and compositions for reducing symptoms of mental concentration dysfunction, mood dysfunction, and/or stress-related dysfunction. In various examples, the methods include selecting a subject experiencing a symptom of mental concentration dysfunction, mood dysfunction, and/or stress-related dysfunction and providing for consumption by the subject, a nicotinamide composition formulated to reduce a frequency and/or severity of the symptom. The nicotinamide composition includes a first component and a second component. In some examples, the first component includes nicotinamide (NAM), nicotinamide riboside, or nicotinamide mononucleotide and the second component includes one or more salts that provide a choline cation and a succinate anion (2−). In certain examples, the molar ratio of the choline cation:succinate anion (2−):first component is between 2:1:0.01 and 2:1:1.